Co-possession of phosphodiesterase type-5 inhibitors (PDE5-I) with nitrates

Current Medical Research and Opinion

Volumn 26, Issue 6, 2010, Pages 1451-1459

  Chang, Li Ling ^a   Ma, Mark ^b   Allmen, Heather Von ^a   Henderson, Scott C ^a   Harper, Kristine ^b   Hornbuckle, Kenneth ^b  

^a IQVIA   (United States)

^b ELI LILLY AND COMPANY   (United States)

Author keywords

Co possession; Erectile dysfunction; Nitrates; Phosphodiesterase type 5 inhibitors; Tadalafil

Indexed keywords

NITRATE; PHOSPHODIESTERASE V INHIBITOR; SILDENAFIL; TADALAFIL; VARDENAFIL;

ADULT; AGED; ARTICLE; COHORT ANALYSIS; COMORBIDITY; CONTROLLED STUDY; DEPRESSION; DIABETES MELLITUS; DRUG CONTRAINDICATION; DRUG EXPOSURE; DRUG SAFETY; ERECTILE DYSFUNCTION; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PRESCRIPTION; UNITED STATES;

ADOLESCENT; ADULT; AGED; CARBOLINES; DATABASES, FACTUAL; DRUG THERAPY, COMBINATION; ERECTILE DYSFUNCTION; HUMANS; IMIDAZOLES; MALE; MIDDLE AGED; NITRATES; PHARMACEUTICAL SERVICES; PHOSPHODIESTERASE INHIBITORS; PHYSICIAN'S PRACTICE PATTERNS; PIPERAZINES; PURINES; SULFONES; TRIAZINES; YOUNG ADULT;

EID: 77952471389     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007991003771874     Document Type: Article

References (15)

1. Kloner RA, Zusman RM. Cardiovascular effects of sildenafil citrate and recommendations for its use. Am J Cardiol 1999;84:11-17N
2. Emmick JT, Stuewe SR, Mitchell M. Overview of the cardiovascular effects of tadalafil. Eur Heart J Supplements 2002;4:H32-47
3. Reffelmann T, Kloner RA. Vardenafil: a selective inhibitor of phosphdiesterase-5 for the treatment of erectile dysfunction. Expert Opin Pharmacother 2007;8:965-974
4. Reffelmann T, Kloner RA. Cardiovascular effects of phosphodiesterase 5 inhibitors. Curr Pharmaceutical Design 2006;12:3485-3494
5. Kloner RA, Jackson G, Emmick JT, et al. Interaction between the phospho-diesterase 5 inhibitor, tadalafil, and the 2 a-blockers doxazosin and tamsu-losin in healthy normotensive men. J Urol 2004;172:1935-1940
6. Webb DJ, Muirhead GJ, Wulff M, et al. Sildenafil citrate potentiates the hypotensive effects of nitric oxide donor drugs in male patients with stable angina. J Am Coll Cardiol 2000;36:25-31
7. Solomon H, Man JW, Jackson G. Erectile dysfunction and the cardiovascular patient: endothelial dysfunction is the common denominator. Heart 2003;89:251-253
8. Kostis JB, Jackson G, Rosen R, et al. Sexual dysfunction and cardiac risk (the Second Princeton Consensus Conference). Am J Cardiol 2005;96:313-321 (Pubitemid 40978596)
9. Bacon CG, Hu FB, Giovannucci E, et al. Association of type and duration of diabetes with erectile dysfunction in a large cohort of men. Diabetes Care 2002;25:1458-1463
10. Sefterl AD, Sun P, Swindle R. The prevalence of hypertension, hyperlipidemia, diabetes mellitus and depression in men with erectile dysfunction. J Urol 2004;171:2341-2345
11. Eng P, Ma M, Zhang X, et al. Codispensing of tadalafil and other phosphodiesterase type 5 inhibitors with contraindicated organic nitrates. Pharmacoepidemiol Drug Saf 2008;17:S1:246
12. Tobi H, Faber A, van den Berg PB, et al. Studying co-medication patterns: the impact of definitions. Pharmacoepidemiol Drug Saf 2007;16:405-411
13. Williams D, Feely J. Initial uptake in use of sildenafil in general practice. Eur J Clin Pharmacol 2001;56:911-914
14. Cheitlin MD, Hutter AM, Brindis RG, et al. Use of sildenafil (Viagra) in patients with cardiovascular disease. J Am Coll Cardiol 1999;33:273-282
15. Kloner RA, Hutter AM, Emmick JT, et al. Time course of the interaction between tadalafil and nitrates. J Am Coll Cardiol 2003;42:1855-1860